MTEM has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
MTEM has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Molecular Templates's total current assets for the quarter that ended in Dec. 2023 was $16.77 Mil.
The historical data trend for Molecular Templates's Total Current Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Molecular Templates Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Total Current Assets | Get a 7-Day Free Trial | 139.90 | 99.38 | 148.22 | 68.30 | 16.77 |
Molecular Templates Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Total Current Assets | Get a 7-Day Free Trial | 68.30 | 51.62 | 11.82 | 22.70 | 16.77 |
Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.
Molecular Templates's Total Current Assets for the fiscal year that ended in Dec. 2023 is calculated as
Total Current Assets | = | Cash, Cash Equivalents, Marketable Securities | + | Total Receivables | + | Total Inventories | + | Other Current Assets |
= | 11.523 | + | 0.25 | + | 0 | + | 4.999 | |
= | 16.77 |
Molecular Templates's Total Current Assets for the quarter that ended in Dec. 2023 is calculated as
Total Current Assets | = | Cash, Cash Equivalents, Marketable Securities | + | Total Receivables | + | Total Inventories | + | Other Current Assets |
= | 11.523 | + | 0.25 | + | 0 | + | 4.999 | |
= | 16.77 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.
Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.
Molecular Templates (NAS:MTEM) Total Current Assets Explanation
In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.
Molecular Templates's Liquidation Value for the quarter that ended in Dec. 2023 is
Liquidation value | |||||||
= | Cash, Cash Equivalents, Marketable Securities | - | Total Liabilities | + | (0.75 * Accounts Receivable) | + | (0.5 * Total Inventories) |
= | 11.523 | - | 31.171 | + | 0.75 * 0 | + | 0.5 * 0 |
= | -19.65 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Molecular Templates's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Maurizio Voi | officer: Chief Medical Officer | 4 MAGUIRE ROAD, LEXINGTON MA 02421 |
Biotech Target N V | 10 percent owner | ARA HILL TOP BUILDING, UNIT A-5, PLETTERIJWEG OOST 1, CURACAO, WILLEMSTAD P8 000000 |
Sean Mclennan | officer: CFO & Treasurer | C/O MOLECULAR TEMPLATES, INC., 93010 AMBERGLEN BLVD., SUITE 100, AUSTIN TX 78729 |
Kevin M. Lalande | director, 10 percent owner | 201 WEST 5TH STREET, AUSTIN TX 78701 |
Shv Management Services, Llc | 10 percent owner | FROST TOWER, 401 CONGRESS AVENUE, SUITE 2950, AUSTIN TX 78701 |
Gabriela Gruia | director | C/O TSCAN THERAPEUTICS, INC., 830 WINTER STREET, WALTHAM MA 02451 |
Jason S. Kim | officer: See Remarks | 9301 AMBERGLEN BOULEVARD, SUITE 100, C/O MOLECULAR TEMPLATES, INC., AUSTIN TX 78729 |
Biotech Ag Bb | 10 percent owner | SCHWERTSTRASSE 6, SCHAFFHAUSEN V8 8200 |
Longitude Capital Partners Iii, Llc | 10 percent owner | 800 EL CAMINO, SUITE 220, MENLO PARK CA 94025 |
Sanders Corazon (corsee) D. | director | C/O MOLECULAR TEMPLATES, INC., 9301 AMBERGLEN BLVD, SUITE 100, AUSTIN VI 78729 |
Patrick G Enright | 10 percent owner | CO LONGITUDE CAPITAL PARTNERS LLC, 800 EL CAMINO REAL, SUITE 220, MENLO PARK CA 94025 |
Bakker Juliet Tammenoms | 10 percent owner | LONGITUDE CAPITAL MANAGEMENT CO., LLC, 800 EL CAMINO REAL, SUITE 220, MENLO PARK CA 94025 |
David Hirsch | director, 10 percent owner | C/O LONGITUDE CAPITAL PARTNERS, LLC, 800 EL CAMINO REAL, SUITE 220, MENLO PARK CA 94025 |
Longitude Venture Partners Iii, L.p. | 10 percent owner | 800 EL CAMINO REAL, SUITE 220, MENLO PARK CA 94025 |
Scott D Morenstein | director | C/O CAXTON ALTERNATIVE MANAGEMENT LP, 1330 SIXTH AVENUE, 20TH FLOOR, NEW YORK NY 10019 |
From GuruFocus
By GuruFocusNews GuruFocusNews • 06-26-2022
By GuruFocusNews GuruFocusNews • 07-01-2022
By sperokesalga sperokesalga • 06-01-2023
By Marketwired • 08-11-2023
By GlobeNewswire GlobeNewswire • 12-02-2022
By sperokesalga sperokesalga • 05-26-2023
By Value_Insider Value_Insider • 11-04-2022
By Marketwired • 11-02-2023
By PurpleRose PurpleRose • 07-11-2022
By sperokesalga sperokesalga • 06-17-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.